Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
Abstract Background The common inflammatory disease multiple sclerosis (MS) is a disease of the central nervous system. For more than 25 years autologous hematopoietic stem cell transplantation (AHSCT) has been used to treat MS. It has been shown to be highly effective in suppressing inflammatory ac...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12944-023-01863-7 |
| _version_ | 1797784415744557056 |
|---|---|
| author | Aina Vaivade Anna Wiberg Payam Emami Khoonsari Henrik Carlsson Stephanie Herman Asma Al-Grety Eva Freyhult Ulla Olsson-Strömberg Joachim Burman Kim Kultima |
| author_facet | Aina Vaivade Anna Wiberg Payam Emami Khoonsari Henrik Carlsson Stephanie Herman Asma Al-Grety Eva Freyhult Ulla Olsson-Strömberg Joachim Burman Kim Kultima |
| author_sort | Aina Vaivade |
| collection | DOAJ |
| description | Abstract Background The common inflammatory disease multiple sclerosis (MS) is a disease of the central nervous system. For more than 25 years autologous hematopoietic stem cell transplantation (AHSCT) has been used to treat MS. It has been shown to be highly effective in suppressing inflammatory activity in relapsing-remitting MS (RRMS) patients. This treatment is thought to lead to an immune system reset, inducing a new, more tolerant system; however, the precise mechanism behind the treatment effect in MS patients is unknown. In this study, the effect of AHSCT on the metabolome and lipidome in peripheral blood from RRMS patients was investigated. Methods Peripheral blood samples were collected from 16 patients with RRMS at ten-time points over the five months course of AHSCT and 16 MS patients not treated with AHSCT. Metabolomics and lipidomics analysis were performed using liquid-chromatography high-resolution mass spectrometry. Mixed linear models, differential expression analysis, and cluster analysis were used to identify differentially expressed features and groups of features that could be of interest. Finally, in-house and in-silico libraries were used for feature identification, and enrichment analysis was performed. Results Differential expression analysis found 657 features in the lipidomics dataset and 34 in the metabolomics dataset to be differentially expressed throughout AHSCT. The administration of cyclophosphamide during mobilization and conditioning was associated with decreased concentrations in glycerophosphoinositol species. Thymoglobuline administration was associated with an increase in ceramide and glycerophosphoethanolamine species. After the conditioning regimen, a decrease in glycerosphingoidlipids concentration was observed, and following hematopoietic stem cell reinfusion glycerophosphocholine concentrations decreased for a short period of time. Ceramide concentrations were strongly associated with leukocyte levels during the procedure. The ceramides Cer(d19:1/14:0) and Cer(d20:1/12:0) were found to be increased (P < .05) in concentration at the three-month follow-up compared to baseline. C16 ceramide, Cer(D18:2/16:0), and CerPE(d16:2(4E,6E)/22:0) were found to be significantly increased in concentration after AHSCT compared to prior to treatment as well as compared to newly diagnosed RRMS patients. Conclusion AHSCT had a larger impact on the lipids in peripheral blood compared to metabolites. The variation in lipid concentration reflects the transient changes in the peripheral blood milieu during the treatment, rather than the changes in the immune system that are assumed to be the cause of clinical improvement within RRMS patients treated with AHSCT. Ceramide concentrations were affected by AHSCT and associated with leukocyte counts and were altered three months after treatment, suggesting a long-lasting effect. |
| first_indexed | 2024-03-13T00:39:35Z |
| format | Article |
| id | doaj.art-510fbe6e321c46e7b1ad0509a8b9084a |
| institution | Directory Open Access Journal |
| issn | 1476-511X |
| language | English |
| last_indexed | 2024-03-13T00:39:35Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj.art-510fbe6e321c46e7b1ad0509a8b9084a2023-07-09T11:23:20ZengBMCLipids in Health and Disease1476-511X2023-07-0122111510.1186/s12944-023-01863-7Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patientsAina Vaivade0Anna Wiberg1Payam Emami Khoonsari2Henrik Carlsson3Stephanie Herman4Asma Al-Grety5Eva Freyhult6Ulla Olsson-Strömberg7Joachim Burman8Kim Kultima9Department of Medical Science, Clinical Chemistry, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Uppsala UniversityDepartment of Biochemistry and Biophysics, Science for Life Laboratory, National Bioinformatics Infrastructure Sweden, Stockholm UniversityDepartment of Medical Science, Clinical Chemistry, Uppsala UniversityDepartment of Medical Science, Clinical Chemistry, Uppsala UniversityDepartment of Medical Science, Clinical Chemistry, Uppsala UniversityDepartment of Cell and Molecular Biology, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Uppsala UniversityDepartment of Medical Science, Neuroscience, Uppsala UniversityDepartment of Medical Science, Clinical Chemistry, Uppsala UniversityAbstract Background The common inflammatory disease multiple sclerosis (MS) is a disease of the central nervous system. For more than 25 years autologous hematopoietic stem cell transplantation (AHSCT) has been used to treat MS. It has been shown to be highly effective in suppressing inflammatory activity in relapsing-remitting MS (RRMS) patients. This treatment is thought to lead to an immune system reset, inducing a new, more tolerant system; however, the precise mechanism behind the treatment effect in MS patients is unknown. In this study, the effect of AHSCT on the metabolome and lipidome in peripheral blood from RRMS patients was investigated. Methods Peripheral blood samples were collected from 16 patients with RRMS at ten-time points over the five months course of AHSCT and 16 MS patients not treated with AHSCT. Metabolomics and lipidomics analysis were performed using liquid-chromatography high-resolution mass spectrometry. Mixed linear models, differential expression analysis, and cluster analysis were used to identify differentially expressed features and groups of features that could be of interest. Finally, in-house and in-silico libraries were used for feature identification, and enrichment analysis was performed. Results Differential expression analysis found 657 features in the lipidomics dataset and 34 in the metabolomics dataset to be differentially expressed throughout AHSCT. The administration of cyclophosphamide during mobilization and conditioning was associated with decreased concentrations in glycerophosphoinositol species. Thymoglobuline administration was associated with an increase in ceramide and glycerophosphoethanolamine species. After the conditioning regimen, a decrease in glycerosphingoidlipids concentration was observed, and following hematopoietic stem cell reinfusion glycerophosphocholine concentrations decreased for a short period of time. Ceramide concentrations were strongly associated with leukocyte levels during the procedure. The ceramides Cer(d19:1/14:0) and Cer(d20:1/12:0) were found to be increased (P < .05) in concentration at the three-month follow-up compared to baseline. C16 ceramide, Cer(D18:2/16:0), and CerPE(d16:2(4E,6E)/22:0) were found to be significantly increased in concentration after AHSCT compared to prior to treatment as well as compared to newly diagnosed RRMS patients. Conclusion AHSCT had a larger impact on the lipids in peripheral blood compared to metabolites. The variation in lipid concentration reflects the transient changes in the peripheral blood milieu during the treatment, rather than the changes in the immune system that are assumed to be the cause of clinical improvement within RRMS patients treated with AHSCT. Ceramide concentrations were affected by AHSCT and associated with leukocyte counts and were altered three months after treatment, suggesting a long-lasting effect.https://doi.org/10.1186/s12944-023-01863-7LipidomicsMetabolomicsAutologous hematopoietic stem cell transplantationRelapsing-remitting multiple sclerosisCeramides |
| spellingShingle | Aina Vaivade Anna Wiberg Payam Emami Khoonsari Henrik Carlsson Stephanie Herman Asma Al-Grety Eva Freyhult Ulla Olsson-Strömberg Joachim Burman Kim Kultima Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients Lipids in Health and Disease Lipidomics Metabolomics Autologous hematopoietic stem cell transplantation Relapsing-remitting multiple sclerosis Ceramides |
| title | Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients |
| title_full | Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients |
| title_fullStr | Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients |
| title_full_unstemmed | Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients |
| title_short | Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients |
| title_sort | autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing remitting multiple sclerosis patients |
| topic | Lipidomics Metabolomics Autologous hematopoietic stem cell transplantation Relapsing-remitting multiple sclerosis Ceramides |
| url | https://doi.org/10.1186/s12944-023-01863-7 |
| work_keys_str_mv | AT ainavaivade autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT annawiberg autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT payamemamikhoonsari autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT henrikcarlsson autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT stephanieherman autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT asmaalgrety autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT evafreyhult autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT ullaolssonstromberg autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT joachimburman autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients AT kimkultima autologoushematopoieticstemcelltransplantationsignificantlyalterscirculatingceramidesinperipheralbloodofrelapsingremittingmultiplesclerosispatients |